Pfizer exceeded expectations with 10% revenue growth and $0.78 adjusted EPS in Q2, raising full-year guidance. Strong sales from cardiovascular and oncology drugs drove shares up 5%. Cost-cutting efforts are boosting earnings. Guidance includes potential US policy changes on drug pricing. Fair value estimate remains $38 per share. Pipeline progress key for future growth.

Pfizer’s cost-cutting initiatives on track to reach $7.2 billion in savings by 2027. Market watches for pipeline advancements to offset patent expirations in 2027 and 2028. Phase 3 data for Padcev expected later this year. Several important phase 3 studies, focused on oncology programs, set to begin this year.

Investors eagerly await Pfizer’s pipeline developments to counter potential revenue declines in 2028-29. Phase 3 data for Padcev in bladder cancer and upcoming studies, including SSGJ-707 and Seagen pipeline, will be pivotal. Author does not own shares in mentioned securities.

Read more at Morningstar: Impressive Q2 Results Bolster 2025, but Awaiting More Pipeline Data